Edition:
India

Galectin Therapeutics Inc (GALT.OQ)

GALT.OQ on NASDAQ Stock Exchange Capital Market

2.49USD
13 Dec 2017
Change (% chg)

-- (--)
Prev Close
$2.49
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
71,848
52-wk High
$3.67
52-wk Low
$0.88

Latest Key Developments (Source: Significant Developments)

Galectin Therapeutics Announces Results From Phase 2b NASH-CX Trial Of GR-MD-02
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Galectin Therapeutics Inc ::GALECTIN THERAPEUTICS ANNOUNCES RESULTS FROM PHASE 2B NASH-CX TRIAL OF ITS PROPRIETARY COMPOUND GR-MD-02.GALECTIN - PHASE 2B TRIAL NASH-CX SHOWED STATISTICALLY SIGNIFICANT RESULTS IN REDUCING PRIMARY ENDPOINT MEASUREMENT OF HVPG VERSUS PLACEBO.GALECTIN - FOR MAJOR SECONDARY ENDPOINT ASSESSMENT OF LIVER BIOPSY, SAW STATISTICALLY SIGNIFICANT EFFECT OF TREATMENT TO IMPROVE HEPATOCYTE BALLOONING.GALECTIN - THERE WAS STATISTICALLY SIGNIFICANT REDUCTION IN DEVELOPMENT OF NEW ESOPHAGEAL VARICES IN PATIENTS WITHOUT VARICES AT BASELINE.GALECTIN-THERE WAS POSITIVE TREND IN TOTAL GROUP,BUT DIFFERENCE DID NOT REACH STATISTICAL SIGNIFICANCE IN REDUCING PRIMARY ENDPOINT MEASUREMENT OF HVPG​‍​.  Full Article

Galectin Therapeutics To Present Results From Phase 2B Nash-Cx Trial On December 5, 2017
Tuesday, 5 Dec 2017 

Dec 4 (Reuters) - Galectin Therapeutics Inc ::GALECTIN THERAPEUTICS TO PRESENT RESULTS FROM PHASE 2B NASH-CX TRIAL ON DECEMBER 5, 2017.  Full Article

Combination Immunotherapy of Pembrolizumab with the Galectin-3 inhibitor gr-md-02 shows promising early results
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Galectin Therapeutics Inc :Combination Immunotherapy of Pembrolizumab with the Galectin-3 inhibitor gr-md-02 shows promising early results in treatment of advanced melanoma from a phase 1b clinical trial.  Full Article

Galectin Therapeutics posts qtrly loss per share $0.13‍​
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Galectin Therapeutics Inc :Galectin Therapeutics Inc - Qtrly loss per share $0.13‍​.Galectin Therapeutics Inc - ‍Top line results of NASH-CX phase 2B clinical trial expected to be announced in early December 2017​.Galectin Therapeutics Inc - ‍Company is funded through february 2018, which is sufficient to report top line data of NASH-CX phase 2B clinical trial​.Galectin Therapeutics - Believes it has sufficient cash to fund currently planned operations and research, development activities through Dec. 31, 2017​.Galectin Therapeutics Inc - ‍As of September 30, 2017, company had $7.0 million of non-restricted cash and cash equivalents​.  Full Article

Galectin Therapeutics Q2 loss per share $0.20
Tuesday, 9 Aug 2016 

Galectin Therapeutics Inc : Q2 loss per share $0.20 . Galectin therapeutics reports second quarter 2016 financial results and provides business update . Q2 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S .Believes it has sufficient cash to fund currently planned operations, research and development activities through june 30, 2017.  Full Article

Galectin Therapeutics quarterly loss per share $0.20
Tuesday, 9 Aug 2016 

Galectin Therapeutics Inc : Believes it has sufficient cash to fund currently planned operations and research, development activities through June 30, 2017 . Quarterly loss per share $0.20 . Quarterly loss per share $0.20 . Top-Line data from Nash-Fx trial in Nash patients with advanced fibrosis expected to be reported by end of Sept - sec filing .Q2 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S.  Full Article

Galectin Therapeutics reports positive mid-stage data on psoriasis drug
Tuesday, 17 May 2016 

Galectin Therapeutics Inc : Drug infusions were well tolerated by patients . Two adverse events were noted, one infiltration of intravenous catheter & one headache during infusion; were mild & transient .Announces Positive Interim Results From Phase 2a Trial With Gr Md-02 in moderate-to-severe plaque psoriasis.  Full Article

Galectin Therapeutics reports Q1 loss $0.24/shr
Tuesday, 10 May 2016 

Galectin Therapeutics Inc : Galectin Therapeutics reports first quarter 2016 financial results and provides business update .Q1 loss per share $0.24.  Full Article

Galectin Therapeutics Inc qtrly loss per share $0.24
Tuesday, 10 May 2016 

Galectin Therapeutics Inc : Galectin Therapeutics Inc qtrly loss per share $0.24 . Believes it has sufficient cash to fund currently planned operations, research and development activities through march 31, 2017 . Q1 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S .Remain on track to report top-line data from 156-patient nash-cx trial in nash patients with cirrhosis by the end of 2017.  Full Article

Galectin slumps after NASH drug misses main goal of mid-stage trial

Galectin Therapeutics Inc said its drug for the complex progressive fatty liver disease NASH led to some clinically meaningful results in patients with cirrhosis, but failed to achieve the main goal of a mid-stage trial, sending its shares plunging 48 percent on Tuesday.